Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pseudoephedrine and PPA

This article was originally published in The Tan Sheet

Executive Summary

Senate passes legislation Nov. 19 limiting the amount of the ingredients that could be sold at retail by a voice vote. Introduced by Sen. John Ashcroft (R-Mo.), the DEFEAT Meth Act (S 486) was the subject of an Aug. 5 Senate Judiciary Committee hearing ("The Tan Sheet" Aug. 16, p. 8). As passed, the bill would set the single transaction limit for non-safe harbor products containing pseudoephedrine or phenylpropanolamine at 9 g. Safe harbor packaging, which would be exempt, is defined as blister packs containing less than a 3 g base of either ingredient with no more than two doses per blister. In addition, the bill requires the Attorney General's office to conduct a study on the practice of converting OTC products containing the ingredients into meth, instructing the office to use information provided by federal and state agencies as well as by pharmaceutical firms. If the AG report finds a "significant number" of OTCs containing the ingredients are used for conversion to meth, a single transaction limit of no less than 24 g could be enacted after a notice and comment period. Mail order exemptions also are included in the measure. Companion legislation (HR 2987) was introduced in the House Sept. 30 by Rep. Chris Cannon (R-Utah)

Related Content

Topics

UsernamePublicRestriction

Register

PS090625

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel